Clancy Paul J 4

What Happened

• Paul J. Clancy, a director of Exact Sciences (EXAS), reported dispositions on 2026-03-23 totaling 26,038 shares (20,640 + 5,398). The Form 4 lists the transactions as dispositions to the issuer (code D) with price shown as N/A; a filing footnote states each share was converted into $105.00 cash as merger consideration. The gross proceeds equal roughly $2,733,990 before any applicable tax withholding.

Key Details

• Transaction date: March 23, 2026 (Effective Time of the merger).
• Form entry price: N/A on the Form 4; footnote clarifies Merger Consideration = $105.00 per share.
• Total shares disposed: 26,038; total gross value ≈ $2,733,990.
• Shares owned after transaction: not reported on the supplied details; common stock was converted into the merger cash consideration (see footnotes).
• Footnotes: F1 describes the merger with Abbott Laboratories and the $105/share cash consideration; F2 notes vested/restricted shares were deemed vested and converted into cash, less any applicable tax withholding.
• Timeliness: Reported with the same transaction date (no late filing indicated in provided info).

Context

• These were not open-market sales but mandatory/contractual conversions of EXAS common stock into cash under the merger agreement (Abbott’s Merger Sub merged into Exact Sciences, making Exact a wholly owned Abbott subsidiary). Such filings reflect a corporate transaction, not necessarily an insider’s voluntary market sale.